EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target

Sven Jonckheere, Jamie Adams, Dominic De Groote, Kyra Campbell, Geert Berx, Steven Goossens

Cells Tissues Organs · 2022 · 211 (2) · 157-182

DOI: 10.1159/000512218 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells Tissues Organs, online erschienen am 05.01.2021. Verfasst von Sven Jonckheere und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Neoplasms. Die Arbeit wurde bisher 167-mal zitiert (Crossref) und nennt 181 Literaturangaben. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastasis is the spread of cancer cells from the primary tumour to distant sites and organs throughout the body. It is the primary cause of cancer morbidity and mortality, and is estimated to account for 90% of cancer-related deaths. During the initial steps of the metastatic cascade, epithelial cancer cells undergo an epithelial-mesenchymal transition (EMT), and as a result become migratory and invasive mesenchymal-like cells while acquiring cancer stem cell properties and therapy resistance. As EMT is involved in such a broad range of processes associated with malignant transformation, it has become an increasingly interesting target for the development of novel therapeutic strategies. Anti-EMT therapeutic strategies could potentially not only prevent the invasion and dissemination of cancer cells, and as such prevent the formation of metastatic lesions, but also attenuate cancer stemness and increase the effectiveness of more classical chemotherapeutics. In this review, we give an overview about the pros and cons of therapies targeting EMT and discuss some already existing candidate drug targets and high-throughput screening tools to identify novel anti-EMT compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionNeoplasmsHumansNeoplastic Stem Cells

Stichwörter der Autor:innen

Drosophila melanogasterDrug screeningEMTMetastasisTherapyZebrafish

Autor:innen und Institutionen

  • Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.
  • Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
  • Department of Biomedical Science, The University of Sheffield, Sheffield, United Kingdom.
  • Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium, Steven.Goossens@ugent.be.
  • Department of Diagnostic Sciences, Ghent University, Ghent, Belgium, Steven.Goossens@ugent.be.

Förderung

  • Wellcome Trust

Zitieren

APA

Jonckheere, S., Adams, J., De Groote, D., Campbell, K., Berx, G., & Goossens, S. (2022). Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target. Cells Tissues Organs, 211(2), 157-182. https://doi.org/10.1159/000512218

Vancouver

Jonckheere S, Adams J, De Groote D, Campbell K, Berx G, Goossens S. Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target. Cells Tissues Organs. 2022;211(2):157-182. doi:10.1159/000512218

BibTeX
@article{Jonckheere2022,
  author = {Jonckheere, Sven and Adams, Jamie and De Groote, Dominic and Campbell, Kyra and Berx, Geert and Goossens, Steven},
  title = {Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target},
  journal = {Cells Tissues Organs},
  year = {2022},
  volume = {211},
  number = {2},
  pages = {157--182},
  doi = {10.1159/000512218}
}
Kostenlos starten →